Allen Bryce K, Stathias Vasileios, Maloof Marie E, Vidovic Dusica, Winterbottom Emily F, Capobianco Anthony J, Clarke Jennifer, Schurer Stephan, Robbins David J, Ayad Nagi G
Department of Psychiatry and Behavioral Sciences, Center for Therapeutic Innovation, University of Miami, Florida, 33136.
J Cell Biochem. 2015 Mar;116(3):351-63. doi: 10.1002/jcb.24990.
There is an urgent need to identify novel therapies for glioblastoma (GBM) as most therapies are ineffective. A first step in this process is to identify and validate targets for therapeutic intervention. Epigenetic modulators have emerged as attractive drug targets in several cancers including GBM. These epigenetic regulators affect gene expression without changing the DNA sequence. Recent studies suggest that epigenetic regulators interact with drivers of GBM cell and stem-like cell proliferation. These drivers include components of the Notch, Hedgehog, and Wingless (WNT) pathways. We highlight recent studies connecting epigenetic and signaling pathways in GBM. We also review systems and big data approaches for identifying patient specific therapies in GBM. Collectively, these studies will identify drug combinations that may be effective in GBM and other cancers.
由于大多数治疗方法对胶质母细胞瘤(GBM)无效,因此迫切需要确定新的治疗方法。这一过程的第一步是识别和验证治疗干预的靶点。表观遗传调节剂已成为包括GBM在内的几种癌症中有吸引力的药物靶点。这些表观遗传调节因子在不改变DNA序列的情况下影响基因表达。最近的研究表明,表观遗传调节因子与GBM细胞和干细胞样细胞增殖的驱动因子相互作用。这些驱动因子包括Notch、Hedgehog和Wingless(WNT)信号通路的组成部分。我们重点介绍了最近将GBM中的表观遗传和信号通路联系起来的研究。我们还综述了用于识别GBM患者特异性治疗方法的系统和大数据方法。总的来说,这些研究将确定可能对GBM和其他癌症有效的药物组合。